Companies/Arbutus Biopharma Corp

Company profile

Arbutus Biopharma Corp

NASDAQ: ABUS · Healthcare · Biotechnology

PublicHQ Warminster, PACIK 0001447028Reports USD

#586 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

61C

FH 64DQ 64GM 47SS 64

v0.1 · 65/100 weight · provisional

↑ Altman-Z, Piotroski F · ↓ 3-yr revenue growth, growth stability

Methodology →

Revenue TTM

$191.4M

Rev growth YoY (TTM)

+2889.9%

Net income (FY)

-$33.5M

Employees

Market cap

$962.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$14.1M$14.1M2025

Net income-$33.5M-$33.5M2025

Operating income-$38.2M-$38.2M2025

Total assets$94.6M$94.6M2025

Liabilities$18.0M$18.0M2025

Equity$76.6M$76.6M2025

Revenue trend

FY2019 – FY2025 · USD

$3.1M

FY19

$6.0M

FY19

$6.9M

FY20

$11.0M

FY21

$39.0M

FY22

$18.1M

FY23

$6.2M

FY24

$14.1M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

License82%

Non-Cash Royalty12%

Service, Other6%

By geography

Not disclosed.

The read

Arbutus Biopharma Corp booked $14.1M in FY2025 revenue, growing 128% year over year — faster than most Healthcare companies we track, at a -237.9% net margin.

Peers · Healthcare

LB Pharmaceuticals Inc Common Stock——Replimune Group, Inc.——Janux Therapeutics, Inc.54D Design Therapeutics, Inc.55C

Key facts

CEOLindsay Androski

SectorHealthcare

IndustryBiotechnology

HeadquartersWarminster, PA

ExchangeNASDAQ: ABUS

Employees19

IPO date2007-07-26

Latest filings

8-K2026-05-27 8-K2026-05-13 10-Q2026-05-13 8-K2026-04-15 DEF 14A2026-04-14 10-K2026-03-23 8-K2026-03-23 8-K2026-03-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.